Last reviewed · How we verify
Febuxostat IR
Febuxostat is a selective xanthine oxidase inhibitor that reduces uric acid production by blocking the enzyme responsible for converting hypoxanthine and xanthine to uric acid.
Febuxostat is a selective xanthine oxidase inhibitor that reduces uric acid production by blocking the enzyme responsible for converting hypoxanthine and xanthine to uric acid. Used for Chronic management of hyperuricemia in patients with gout, Prevention of gout flares.
At a glance
| Generic name | Febuxostat IR |
|---|---|
| Also known as | Uloric |
| Sponsor | Takeda |
| Drug class | Xanthine oxidase inhibitor |
| Target | Xanthine oxidase |
| Modality | Small molecule |
| Therapeutic area | Rheumatology |
| Phase | Phase 3 |
Mechanism of action
Febuxostat selectively inhibits xanthine oxidase, the key enzyme in the final steps of purine metabolism. By blocking this enzyme, it decreases serum and urinary uric acid levels, preventing urate crystal formation and deposition in joints and tissues. This mechanism is used to manage hyperuricemia and prevent gout attacks.
Approved indications
- Chronic management of hyperuricemia in patients with gout
- Prevention of gout flares
Common side effects
- Liver function test abnormalities
- Gout flare (during initiation)
- Nausea
- Arthralgia
- Rash
Key clinical trials
- Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout (PHASE3)
- Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Febuxostat IR CI brief — competitive landscape report
- Febuxostat IR updates RSS · CI watch RSS
- Takeda portfolio CI